Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer

NCT02236637 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.

NCT NCT02236637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02236637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Phase
Observational
Overall status
Completed
Start date
June 14, 2013
Completion date
November 21, 2018
Enrollment
3,050 (actual)
Sites
146

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer